US20110125090A1 - Ophthalmic drug delivery system and method - Google Patents
Ophthalmic drug delivery system and method Download PDFInfo
- Publication number
- US20110125090A1 US20110125090A1 US12/985,758 US98575811A US2011125090A1 US 20110125090 A1 US20110125090 A1 US 20110125090A1 US 98575811 A US98575811 A US 98575811A US 2011125090 A1 US2011125090 A1 US 2011125090A1
- Authority
- US
- United States
- Prior art keywords
- shaped
- configuration
- lens capsule
- eye
- implanting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- the FIGURE shows a embodiments of the device.
- Topical drug deliver must be repeated many times on a daily basis because of low or slow penetration. Compliance is also a problem.
- Subconjunctival drug delivery can be painful and has slow drug penetration.
- Intravitreal drug delivery has a short duration, typically of 2 to 30 days, so additional intervention and/or repeated injections are needed.
- the possibility of potential infections and retinal injury are also problems.
- Scleral implants and trans-scleral implants have not been attempted or tested.
- the implanted devices usually are made of polymers; there is usually slow intraocular penetration when polymers are injected into the eye.
- the vitreous usually requires additional intervention with attendant potential complications, such as infection, retinal injury, etc.
- the disclosed system and method uses the capsular bag, obtained during or after cataract extraction, as a polymeric slow release drug delivery system and method. It is used for drug delivery and for simultaneous support for the lens capsule.
- the inventive system is used during or after intra-ocular surgery for cataract extraction in the same session. After an opening in the anterior chamber is made, a circular area of the anterior capsule is removed to extract the lens cortex and nucleus.
- the system and method is used post-surgically to prevent or to treat inflammation. After surgery, most if not all eyes have some inflammation for which treatment is administered. For example, all patients who have diabetic retinopathy have post-surgical ocular inflammation. All patients who have a previous history of uveitis have more excessive inflammation.
- the device is a capsular ring of any size configured in a shape for implanting outside the crystalline lens.
- the device is not dependent on removal of the crystalline lens.
- the device is intraocular but is extralens, it is external to the lens. It is supported in the eye by the lens zonules or ciliary body.
- the device is a capsular ring of any size configured in a shape for implanting over the lens capsule having an intraocular lens.
- the device is configured for implanting between the iris and the outer part of the lens capsule.
- the device shape fits its position, that is, its location, inside the eye.
- the length of the device fits a large space inside the eye, and provides a longer duration of agent release over a wider area inside the eye than known devices.
- the device is configured for implanting anterior to the lens.
- the device is configured either C-shaped or ring shaped to lay on the zonules or the anterior lens capsule or the intraocular lens (IOL). Any other device shape would not be stable in this position, that is, this location.
- the device is configured for implanting in the choroid.
- the device is configured either as a rod or as a snake-shaped semicircle. In these configurations, the device follows the inside curvature of the sclera and can readily snake inside the suprachoroidal space. Any other device shape would be difficult to configure in the suprachoroidal space, and could penetrate the choroid and the retina resulting in serious complications. Any other device shape may not sufficiently large to cover a relatively large area.
- the device is configured for implanting under the retina, that is, for subretinal implantation.
- the device is configured either as a rod or as a semicircle, following the curvature of the retina and the subretinal space.
- a circular device may be implanted under the retina, implanting would be difficult.
- a circular device would not follow the retinal curvature and would bulge the retina.
- the device is biodegradable, also termed bioadsorbable; no foreign body remains in the eye after the device is absorbed.
- the FIGURE shows various embodiments of the device.
- the device is rod shaped and may be straight, curved, C-shaped, closed loop, Its length ranges from 1 mm to 60 mm inclusive. In one embodiment, its length ranges from 15 mm to 600 mm inclusive. Its diameter ranges from 30 micrometers to 3 millimeters inclusive and is round, flat, bead-shaped, etc.
- the device is made of biodegradable polymers that contain and release agent contained within the device and/or within the polymers. In one embodiment the device is solid. In one embodiment the device is not-solid. In either embodiment, the device may be sized to be between 8 mm diameter and 18 mm diameter, inclusive.
- the device is shaped as a rod, tube, open loop, or closed loop.
- the device can be a solid rod or a hollow tube with closed ends.
- the device is folded for easy implanting through an incision that is as small as 1 mm. The nanlded over the lens capsule in the posterior chamber. For implanting, a viscoelastic substance is also implanted for lubrication and ease of implantation, as known to one skilled in the art. Once the device is it in place, the device is unfolded.
- the device is shaped as a rod, tube or open loop. It is not shaped as a closed loop.
- the device is implanted under the sclera over the ciliary body or the choroid of the eye through a small incision, preferably in the sclera at the plars plana area 1 mm to 4 mm behind the limbus of the cornea/sclera junction, or anywhere else in the sclera.
- the incision reaches the ciliary body/choroid.
- the space between the ciliary body/choroid and the sclera is called suprachoroidal space.
- the device which has a semicircular or straight rod configuration is threaded in the suprachoroidal space in any desired direction toward any meridian.
- the resilient structure of the device assists in moving it in this space to the desired length. Because of its round tip, it cannot penetrate the choroidal vessels but follows the suprachoroida space when pushed against the resilient sclera. Its location can also be verified by indirect ophthalmoscopy. After the implantation, the scleral incision is closed with a suture.
- the device is shaped as a rod, tube, or semicircle.
- the device is implanted through a pars plana vitrectomy through the sclera.
- a subretinal bleb is created using a balanced saline solution at the desired retinal location, e.g., in the superior retina.
- forceps the device is inserted gently into the subretinal space where it remains until it is adsorbed. It is known that material injected under the retina, with time, diffuses from that location into the subretinal space under the macula and exerts a therapeutic effect.
- Implantation methods are known to one skilled in the art. Implantation may use forceps. Implantation may use an injector.
- the device contains agents that are neuronal cell protective and/or neuronal cell proliferative.
- the agents can be on the device, in the device, both on and in the device, and/or administered with the device by, e.g., simultaneous or substantially simultaneous injection upon implantation.
- Such devices are used for implanting in patients with glaucoma, neurodegenerative diseases including dry or wet forms of age related macular degeneration (ARMD), retinitis pigmentosa where the retinal cells and retinal pigment epithelial cells die by aging and genetic/inflammatory predisposition, and diabetic retinopathy.
- age related macular degeneration AMD
- retinitis pigmentosa where the retinal cells and retinal pigment epithelial cells die by aging and genetic/inflammatory predisposition
- diabetic retinopathy diabetic retinopathy.
- ROCK rho kinase
- ROCK plays an important role in cell proliferation, cell differentiation and cell survival/death. Blockade of ROCK promotes axonal regeneration and neuron survival in vivo and in vitro, thereby exhibiting potential clinical applications in spinal cord damage and stroke.
- ROCK inhibitors attenuated increases in pulmonary arterial pressures in response to intravenous injections of serotonin, angiotensin II, and Bay K 8644.
- ARMD can have an inflammatory component, contributing to cell death and apoptosis. Oxidative and ischemic injury in ARMD and diabetic retinopathy also contributes to ROCK activation. Because ROCK plays an important role in these processes, inhibiting ROCK can prevent neuronal cell death.
- ROCK inhibitors are injected directly into the eye, e.g., in the vitreous cavity, under the retina, under the choroid, etc.
- Methods and formulations are disclosed in the following references, each of which is expressly incorporated by reference in its entirety: Peyman et al. Retina 7 (1987) 227; Khoobehi et al., Ophthalmic Surg. 22 (1991) 175; Berger etl al., Investigative Ophthamology & Visual Science, 37 (1996) 2318; Berger etl al., Investigative Ophthamology & Visual Science, 35 (1994) 1923.
- ROCK inhibitors are injected in a polymeric formulation to provide a slow release system.
- the polymeric material is made from any biodegradable polymer as known to one skilled in the art.
- suitable materials include, but are not limited to, polymers and/or co-polymers (poly)lactic acid (PLA), (poly)glycolic acid (PGA), lactic acid, (poly)caprolactone, collagen, etc. These can be injected or implanted in a shape and location as described above.
- ROCK inhibitors are administered in a slow release system.
- ROCK inhibitors are administered with one or more other agents that inhibit inflammatory processes, inhibit angiogenesis, and/or inhibit fibrosis.
- agents include, but are not limited to, vascular endothelial growth factor (VEGF) inhibitors, platelet-derived growth factor (PDGF) inhibitors, and integrin inhibitors.
- VEGF vascular endothelial growth factor
- PDGF platelet-derived growth factor
- integrin inhibitors vascular endothelial growth factor
- ROCK inhibitors are administered in a non-slow release form, and VEGF, PDGF, and/or integrin inhibitors are administered in a slow release form.
- ROCK inhibitors and VEGF, PDGF, and/or integrin inhibitors are administered in a dual, triple, or quadruple slow release form.
- ROCK inhibitors include, but are not limited to, the following agents: fasudil hydrochloride (inhibitor of cyclic nucleotide dependent- and rho kinases); GSK 429286 (a selective ROCK inhibitors); H 1152 dihydrochloride (a selective ROCK inhibitor); glycyl-H 1152 dihydrochloride (a more selective analog of H 1152 dihydrochloride); HA 1100 hydrochloride (a cell-permeable, selective ROCK inhibitor); SR 3677 hydrochloride (a potent, selective ROCK inhibitor); Y 39983 dihydrochloride (a selective ROCK inhibitor); and Y 27632 dihydrochloride a selective p160 ROCK inhibitor).
- VEGF inhibitors include, but are not limited to, Avastin, Lucentes, etc.
- PDGF inhibitors include, but are not limited to, Sunitinib. Integrin inhibitors are known to one skilled in the art.
- the concentration of ROCK inhibitor is administered so that its concentration upon release ranges from less than 1 micromol to 1 millimole. In one embodiment, the concentration of agent is administered so that its concentration upon release ranges from 1 micromole/day to 100 micromol day. Such concentrations are effective and are non-toxic.
- the agents may be in any biocompatible formation as known to one skilled in the art.
- the agents may be formulated as microspheres, microcapsules, liposomes, nanospheres, nanoparticles, etc. as known to one skilled in the art.
- the general configuration of the device is new.
- the device is implanted by any of three different methods in various parts of the eye.
- the device is configured for implanting over the lens capsule and between the iris and the lens in the posterior chamber.
- the device is configured for implanting in the suprachoroidal space; in this embodiment, agent contained in and/or on or with the device is delivered to the choroid and retina.
- the device is configured for implanting in the subretinal space; in this embodiment, agent contained in and/or on or with the device is delivered to the sensory retina.
- the device may be of any shape. The following embodiments are illustrative only and are not limiting.
- the device is ring shaped.
- the device is shaped as an open ring (e.g., doughnut or tire shape).
- the device is shaped as a rod, which may be straight or curved.
- the device is shaped as a semicircle.
- the device contains one ring.
- the device contains at least two concentric rings.
- the device is shaped as an oval.
- the device is C shaped.
- the device is shaped as triangle.
- the device is shaped as a quadratic.
- the device is spring-shaped.
- the device is shaped in a zigzag configuration.
- a tube structure permits delivery of agent that must be in a liquid medium, such agents include agents for gene modification or stem cells.
- the size of the device ranges from 1 mm in diameter up to about 34 mm in diameter. In one embodiment, the size of the device ranges from 1 mm in diameter up to about 20 mm in diameter. In one embodiment, the thickness of the device may range from about 50 ⁇ m to about 3000 ⁇ m. In one embodiment, the thickness of the device may range from about 10 ⁇ m to about 3000 ⁇ m. In one embodiment, the device is made from a polymeric material that is absorbable. In one embodiment, the device is made from a polymeric material that is nonabsorbable, e.g., polylactic acid polyglycolic acid, silicone, acrylic, polycaprolactone, etc. In one embodiment, the device is made as microspheres.
- the device is positioned in the lens capsule, e.g., after cataract extraction prior to or after IOL implantation. In one embodiment, it is positioned inside the lens capsule after cataract extraction and acts as a polymeric capsular expander keeping the capsular bag open for intraocular lens (IOL) implantation). In one embodiment, the device is positioned on the haptics of the IOL. In one embodiment, the device is located inside the capsule or under the iris supported by the lens zonules, or it can be sufficiently large to lie in the ciliary sulcus, or ciliary body, or hanging from the zonules in a C-shaped configuration.
- the inventive device is implanted before or after an IOL is implanted.
- the inventive device is flexible, deformable, and re-moldable.
- the inventive device is implanted through a incision one mm or less using an injector, forceps, etc. The incision may be made in the cornea for cataract removal.
- the inventive device is implanted in an eye without cataract extraction.
- the inventive device may be implanted under the iris, e.g., after traumatic anterior segment injury, and lies over the crystalline lens, IOL, and zonules. Implantation may be facilitated by using a visco-elastic material such as healon, methyl cellulose, etc.
- Retino-choroidal diseases are aggravated after cataract surgery.
- Retino-choroidal diseases include, but are not limited to, diabetes, existing prior inflammations such as uveitis, vascular occlusion, wet age related macular degeneration, etc. Patients with these diseases are candidates for the inventive drug delivery system and method.
- Other indications are prophylactic therapy prior to development of retinal complications, such as inflammation (CME) and infection, and therapy for an existing disease.
- Other indications are conditions in which any intraocular drug delivery to treat aging processes if cataract surgery is contemplated or after IOL implantation. In latter situation, the inventive device can be implanted in the capsule or over the IOL under the iris
- Other indications are post-surgical inflammations, post-surgical infections such as after cataract extraction, and any intraocular delivery.
- medication can be coated on a surface and eluted from the surface of the inventive device for delivery, using methods known in the art (e.g., drug-coated stents).
- medication can be incorporated in the polymeric material using methods known to one skilled in the art.
- the following medications can be delivered, alone or in combinations, to treat eyes using the inventive system and method: steroids, non-steroidal anti-inflammatory drugs (NSAIDS), antibiotics, anti-fungals, antioxidants, macrolides including but not limited to cyclosporine, tacrolimis, rapamycin, mycophenolic acid and their analogs, etc.
- voclosporin is a next generation calcineurin inhibitor, an immunosuppressive compound, developed for the treatment of uveitis, an inflammation of the uvea, the treatment of psoriasis, and for the prevention of organ rejection in renal transplant patients. It can be used with other immunomodulatores, etanercept, infliximab, adalimumab, etc.
- antibodies e.g., anti-vascular endothelial growth factor
- immunomodulators e.g., antiproliferative agents
- gene delivery agents e.g., to treat damaged neuronal tissue
- neuroprotective agents e.g., to treat or prevent increases in intraocular pressure, etc.
- combinations of agents may be provided in a single device or in multiple devices.
- the duration of delivery is manipulated so that the agent(s) is released at a quantity needed to achieve therapeutic effect for each agent, if more than one agent is administered, as long as necessary. Duration may be a single dose, may be one day, may be daily for up to 12 months or longer, may be several times a day. In embodiments using a polymer, reimplantation is possible through a small incision once the polymer is absorbed.
Abstract
An ocular device comprising a biodegradable, and absorbable body configured in a shape for implanting
-
- directly exterior and anterior to a crystalline lens capsule in a patient's eye shaped in a C configuration or a ring configuration to stably lay on zonules or the anterior lens capsule or an intraocular lens (IOL) between an iris and an outer surface of the lens capsule, or
- in the choroid shaped in straight rod configuration or in a snake-shaped semicircle configuration to follow the inside curvature of the sclera and readily position inside the suprachoroidal space, or
- under the retina shaped in a rod configuration or a semicircle configuration
the device comprising a deformable material such that the device is folded upon implantation, the device optionally containing an ocular therapeutic agent released upon implanting in the patient's eye.
Description
- This application is a CIP of U.S. application Ser. No. 12/611,682 filed Nov. 3, 2009, which claims priority from U.S. Application No. 61/114,143 filed Nov. 13, 2008, the contents of which are expressly incorporated by reference herein in its entirety.
- The FIGURE shows a embodiments of the device.
- Known methods of drug delivery to the eye have drawbacks, as the following illustrations demonstrate. Topical drug deliver must be repeated many times on a daily basis because of low or slow penetration. Compliance is also a problem. Subconjunctival drug delivery can be painful and has slow drug penetration. Intravitreal drug delivery has a short duration, typically of 2 to 30 days, so additional intervention and/or repeated injections are needed. The possibility of potential infections and retinal injury are also problems. Scleral implants and trans-scleral implants have not been attempted or tested. The implanted devices usually are made of polymers; there is usually slow intraocular penetration when polymers are injected into the eye. The vitreous usually requires additional intervention with attendant potential complications, such as infection, retinal injury, etc.
- Method of intraocular delivery of various therapeutic agents and methods are disclosed in Peyman et al., Retina, The Journal of Retinal and Vitreous Diseases 29 (2009) 875-912, which is expressly incorporated by reference in its entirety.
- The disclosed system and method uses the capsular bag, obtained during or after cataract extraction, as a polymeric slow release drug delivery system and method. It is used for drug delivery and for simultaneous support for the lens capsule.
- The inventive system is used during or after intra-ocular surgery for cataract extraction in the same session. After an opening in the anterior chamber is made, a circular area of the anterior capsule is removed to extract the lens cortex and nucleus.
- In one embodiment, the system and method is used post-surgically to prevent or to treat inflammation. After surgery, most if not all eyes have some inflammation for which treatment is administered. For example, all patients who have diabetic retinopathy have post-surgical ocular inflammation. All patients who have a previous history of uveitis have more excessive inflammation.
- In one embodiment, the device is a capsular ring of any size configured in a shape for implanting outside the crystalline lens. Thus, the device is not dependent on removal of the crystalline lens. In this embodiment, the device is intraocular but is extralens, it is external to the lens. It is supported in the eye by the lens zonules or ciliary body.
- In one embodiment, the device is a capsular ring of any size configured in a shape for implanting over the lens capsule having an intraocular lens. In this embodiment, where the eye contains an intraocular lens, the device is configured for implanting between the iris and the outer part of the lens capsule.
- It is important that the device shape fits its position, that is, its location, inside the eye. The length of the device fits a large space inside the eye, and provides a longer duration of agent release over a wider area inside the eye than known devices.
- In one embodiment, the device is configured for implanting anterior to the lens. In this embodiment, the device is configured either C-shaped or ring shaped to lay on the zonules or the anterior lens capsule or the intraocular lens (IOL). Any other device shape would not be stable in this position, that is, this location.
- In one embodiment, the device is configured for implanting in the choroid. In this embodiment, the device is configured either as a rod or as a snake-shaped semicircle. In these configurations, the device follows the inside curvature of the sclera and can readily snake inside the suprachoroidal space. Any other device shape would be difficult to configure in the suprachoroidal space, and could penetrate the choroid and the retina resulting in serious complications. Any other device shape may not sufficiently large to cover a relatively large area.
- In one embodiment, the device is configured for implanting under the retina, that is, for subretinal implantation. In this embodiment, the device is configured either as a rod or as a semicircle, following the curvature of the retina and the subretinal space. Although a circular device may be implanted under the retina, implanting would be difficult. A circular device would not follow the retinal curvature and would bulge the retina.
- In all embodiments the device is biodegradable, also termed bioadsorbable; no foreign body remains in the eye after the device is absorbed.
- The FIGURE shows various embodiments of the device. The device is rod shaped and may be straight, curved, C-shaped, closed loop, Its length ranges from 1 mm to 60 mm inclusive. In one embodiment, its length ranges from 15 mm to 600 mm inclusive. Its diameter ranges from 30 micrometers to 3 millimeters inclusive and is round, flat, bead-shaped, etc. The device is made of biodegradable polymers that contain and release agent contained within the device and/or within the polymers. In one embodiment the device is solid. In one embodiment the device is not-solid. In either embodiment, the device may be sized to be between 8 mm diameter and 18 mm diameter, inclusive.
- The device is shaped as a rod, tube, open loop, or closed loop. In embodiments where the device is a rod, the device can be a solid rod or a hollow tube with closed ends. The device is folded for easy implanting through an incision that is as small as 1 mm. The nanlded over the lens capsule in the posterior chamber. For implanting, a viscoelastic substance is also implanted for lubrication and ease of implantation, as known to one skilled in the art. Once the device is it in place, the device is unfolded.
- For a suprachoroidal implantation application, the device is shaped as a rod, tube or open loop. It is not shaped as a closed loop. The device is implanted under the sclera over the ciliary body or the choroid of the eye through a small incision, preferably in the sclera at the plars plana area 1 mm to 4 mm behind the limbus of the cornea/sclera junction, or anywhere else in the sclera. The incision reaches the ciliary body/choroid. The space between the ciliary body/choroid and the sclera is called suprachoroidal space. The device which has a semicircular or straight rod configuration is threaded in the suprachoroidal space in any desired direction toward any meridian. The resilient structure of the device assists in moving it in this space to the desired length. Because of its round tip, it cannot penetrate the choroidal vessels but follows the suprachoroida space when pushed against the resilient sclera. Its location can also be verified by indirect ophthalmoscopy. After the implantation, the scleral incision is closed with a suture.
- For a subretinal implantation application, the device is shaped as a rod, tube, or semicircle. The device is implanted through a pars plana vitrectomy through the sclera. A subretinal bleb is created using a balanced saline solution at the desired retinal location, e.g., in the superior retina. Using forceps, the device is inserted gently into the subretinal space where it remains until it is adsorbed. It is known that material injected under the retina, with time, diffuses from that location into the subretinal space under the macula and exerts a therapeutic effect.
- Implantation methods are known to one skilled in the art. Implantation may use forceps. Implantation may use an injector.
- In one embodiment, the device contains agents that are neuronal cell protective and/or neuronal cell proliferative. The agents can be on the device, in the device, both on and in the device, and/or administered with the device by, e.g., simultaneous or substantially simultaneous injection upon implantation. Such devices are used for implanting in patients with glaucoma, neurodegenerative diseases including dry or wet forms of age related macular degeneration (ARMD), retinitis pigmentosa where the retinal cells and retinal pigment epithelial cells die by aging and genetic/inflammatory predisposition, and diabetic retinopathy.
- One non-limiting example of such an agent is rho kinase (ROCK). ROCK plays an important role in cell proliferation, cell differentiation and cell survival/death. Blockade of ROCK promotes axonal regeneration and neuron survival in vivo and in vitro, thereby exhibiting potential clinical applications in spinal cord damage and stroke. ROCK inhibitors attenuated increases in pulmonary arterial pressures in response to intravenous injections of serotonin, angiotensin II, and Bay K 8644. Y-27632, sodium nitrite, and BAY 41-8543, a guanylate cyclase stimulator, decreased pulmonary and systemic arterial pressures and vascular resistances in monocrotaline-treated rats.
- Its use to prevent and/or treat in degenerative retinal diseases such as ARMD, retinitis pigmentosa, and glaucoma has not been reported and thus is new. ARMD can have an inflammatory component, contributing to cell death and apoptosis. Oxidative and ischemic injury in ARMD and diabetic retinopathy also contributes to ROCK activation. Because ROCK plays an important role in these processes, inhibiting ROCK can prevent neuronal cell death.
- In one embodiment, ROCK inhibitors are injected directly into the eye, e.g., in the vitreous cavity, under the retina, under the choroid, etc. Methods and formulations are disclosed in the following references, each of which is expressly incorporated by reference in its entirety: Peyman et al. Retina 7 (1987) 227; Khoobehi et al., Ophthalmic Surg. 22 (1991) 175; Berger etl al., Investigative Ophthamology & Visual Science, 37 (1996) 2318; Berger etl al., Investigative Ophthamology & Visual Science, 35 (1994) 1923. In one embodiment, ROCK inhibitors are injected in a polymeric formulation to provide a slow release system. In this embodiment, the polymeric material is made from any biodegradable polymer as known to one skilled in the art. Examples of suitable materials include, but are not limited to, polymers and/or co-polymers (poly)lactic acid (PLA), (poly)glycolic acid (PGA), lactic acid, (poly)caprolactone, collagen, etc. These can be injected or implanted in a shape and location as described above. In one embodiment, ROCK inhibitors are administered in a slow release system.
- In one embodiment, ROCK inhibitors are administered with one or more other agents that inhibit inflammatory processes, inhibit angiogenesis, and/or inhibit fibrosis. Such agents include, but are not limited to, vascular endothelial growth factor (VEGF) inhibitors, platelet-derived growth factor (PDGF) inhibitors, and integrin inhibitors. In one embodiment, ROCK inhibitors are administered in a non-slow release form, and VEGF, PDGF, and/or integrin inhibitors are administered in a slow release form. In one embodiment ROCK inhibitors are administered in a slow release form, and VEGF, PDGF, and/or integrin inhibitors are administered in a non-slow release form. In one embodiment, ROCK inhibitors and VEGF, PDGF, and/or integrin inhibitors are administered in a dual, triple, or quadruple slow release form.
- Examples of ROCK inhibitors include, but are not limited to, the following agents: fasudil hydrochloride (inhibitor of cyclic nucleotide dependent- and rho kinases); GSK 429286 (a selective ROCK inhibitors); H 1152 dihydrochloride (a selective ROCK inhibitor); glycyl-H 1152 dihydrochloride (a more selective analog of H 1152 dihydrochloride); HA 1100 hydrochloride (a cell-permeable, selective ROCK inhibitor); SR 3677 hydrochloride (a potent, selective ROCK inhibitor); Y 39983 dihydrochloride (a selective ROCK inhibitor); and Y 27632 dihydrochloride a selective p160 ROCK inhibitor). VEGF inhibitors include, but are not limited to, Avastin, Lucentes, etc. PDGF inhibitors include, but are not limited to, Sunitinib. Integrin inhibitors are known to one skilled in the art.
- The concentration of ROCK inhibitor is administered so that its concentration upon release ranges from less than 1 micromol to 1 millimole. In one embodiment, the concentration of agent is administered so that its concentration upon release ranges from 1 micromole/day to 100 micromol day. Such concentrations are effective and are non-toxic.
- The agents may be in any biocompatible formation as known to one skilled in the art. The agents may be formulated as microspheres, microcapsules, liposomes, nanospheres, nanoparticles, etc. as known to one skilled in the art.
- The general configuration of the device is new. The device is implanted by any of three different methods in various parts of the eye. In one method, the device is configured for implanting over the lens capsule and between the iris and the lens in the posterior chamber. In one method, the device is configured for implanting in the suprachoroidal space; in this embodiment, agent contained in and/or on or with the device is delivered to the choroid and retina. In one method, the device is configured for implanting in the subretinal space; in this embodiment, agent contained in and/or on or with the device is delivered to the sensory retina.
- In an intralens device, the device may be of any shape. The following embodiments are illustrative only and are not limiting. In one embodiment, the device is ring shaped. In one embodiment, the device is shaped as an open ring (e.g., doughnut or tire shape). In one embodiment, the device is shaped as a rod, which may be straight or curved. In one embodiment, the device is shaped as a semicircle. In one embodiment, the device contains one ring. In one embodiment, the device contains at least two concentric rings. In one embodiment, the device is shaped as an oval. In one embodiment, the device is C shaped. In one embodiment, the device is shaped as triangle. In one embodiment, the device is shaped as a quadratic. In one embodiment, the device is spring-shaped. In one embodiment, the device is shaped in a zigzag configuration. A tube structure permits delivery of agent that must be in a liquid medium, such agents include agents for gene modification or stem cells.
- In one embodiment, the size of the device ranges from 1 mm in diameter up to about 34 mm in diameter. In one embodiment, the size of the device ranges from 1 mm in diameter up to about 20 mm in diameter. In one embodiment, the thickness of the device may range from about 50 μm to about 3000 μm. In one embodiment, the thickness of the device may range from about 10 μm to about 3000 μm. In one embodiment, the device is made from a polymeric material that is absorbable. In one embodiment, the device is made from a polymeric material that is nonabsorbable, e.g., polylactic acid polyglycolic acid, silicone, acrylic, polycaprolactone, etc. In one embodiment, the device is made as microspheres.
- The device is positioned in the lens capsule, e.g., after cataract extraction prior to or after IOL implantation. In one embodiment, it is positioned inside the lens capsule after cataract extraction and acts as a polymeric capsular expander keeping the capsular bag open for intraocular lens (IOL) implantation). In one embodiment, the device is positioned on the haptics of the IOL. In one embodiment, the device is located inside the capsule or under the iris supported by the lens zonules, or it can be sufficiently large to lie in the ciliary sulcus, or ciliary body, or hanging from the zonules in a C-shaped configuration.
- For implantation, after removing the lens cortex and nucleus inside the capsule through a capsulotomy, the inventive device is implanted before or after an IOL is implanted. The inventive device is flexible, deformable, and re-moldable. In one embodiment, the inventive device is implanted through a incision one mm or less using an injector, forceps, etc. The incision may be made in the cornea for cataract removal. In one embodiment, the inventive device is implanted in an eye without cataract extraction. In this embodiment the inventive device may be implanted under the iris, e.g., after traumatic anterior segment injury, and lies over the crystalline lens, IOL, and zonules. Implantation may be facilitated by using a visco-elastic material such as healon, methyl cellulose, etc.
- Retino-choroidal diseases are aggravated after cataract surgery. Retino-choroidal diseases include, but are not limited to, diabetes, existing prior inflammations such as uveitis, vascular occlusion, wet age related macular degeneration, etc. Patients with these diseases are candidates for the inventive drug delivery system and method. Other indications are prophylactic therapy prior to development of retinal complications, such as inflammation (CME) and infection, and therapy for an existing disease. Other indications are conditions in which any intraocular drug delivery to treat aging processes if cataract surgery is contemplated or after IOL implantation. In latter situation, the inventive device can be implanted in the capsule or over the IOL under the iris Other indications are post-surgical inflammations, post-surgical infections such as after cataract extraction, and any intraocular delivery.
- In one embodiment, medication can be coated on a surface and eluted from the surface of the inventive device for delivery, using methods known in the art (e.g., drug-coated stents). In one embodiment, medication can be incorporated in the polymeric material using methods known to one skilled in the art. The following medications can be delivered, alone or in combinations, to treat eyes using the inventive system and method: steroids, non-steroidal anti-inflammatory drugs (NSAIDS), antibiotics, anti-fungals, antioxidants, macrolides including but not limited to cyclosporine, tacrolimis, rapamycin, mycophenolic acid and their analogs, etc. For example, voclosporin (FIG.) is a next generation calcineurin inhibitor, an immunosuppressive compound, developed for the treatment of uveitis, an inflammation of the uvea, the treatment of psoriasis, and for the prevention of organ rejection in renal transplant patients. It can be used with other immunomodulatores, etanercept, infliximab, adalimumab, etc. Other examples include: antibodies (e.g., anti-vascular endothelial growth factor), immunomodulators, antiproliferative agents, gene delivery agents (e.g., to treat damaged neuronal tissue), neuroprotective agents, anti-glaucoma agents (e.g., to treat or prevent increases in intraocular pressure, etc.). In one embodiment, combinations of agents may be provided in a single device or in multiple devices.
- The duration of delivery is manipulated so that the agent(s) is released at a quantity needed to achieve therapeutic effect for each agent, if more than one agent is administered, as long as necessary. Duration may be a single dose, may be one day, may be daily for up to 12 months or longer, may be several times a day. In embodiments using a polymer, reimplantation is possible through a small incision once the polymer is absorbed.
- Other variations or embodiments will be apparent to a person of ordinary skill in the art from the above description. Thus, the foregoing embodiments are not to be construed as limiting the scope of the claimed invention.
Claims (5)
1. An ocular device comprising a biodegradable, and absorbable body configured in a shape for implanting
directly exterior and anterior to a crystalline lens capsule in a patient's eye shaped in a C configuration or a ring configuration to stably lay on zonules or the anterior lens capsule or an intraocular lens (IOL) between an iris and an outer surface of the lens capsule, or
in the choroid shaped in straight rod configuration or in a snake-shaped semicircle configuration to follow the inside curvature of the sclera and readily position inside the suprachoroidal space, or
under the retina shaped in a rod configuration or a semicircle configuration
the device comprising a deformable material such that the device is folded upon implantation, the device optionally containing an ocular therapeutic agent released upon implanting in the patient's eye.
2. The device of claim 1 sized between 8 mm diameter and 18 mm diameter, inclusive.
3. A method of treating a patient by administering the device of claim 1 and intravitreally injecting the ocular therapeutic agent.
4. The device of claim 1 containing a liquid medium in which an agent is suspended.
5. The device of claim 1 containing a therapeutic agent in the device.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/985,758 US20110125090A1 (en) | 2008-11-13 | 2011-01-06 | Ophthalmic drug delivery system and method |
US13/457,568 US9486357B2 (en) | 2008-11-13 | 2012-04-27 | Ophthalmic drug delivery system and method |
US15/269,444 US10272035B2 (en) | 2008-11-13 | 2016-09-19 | Ophthalmic drug delivery method |
US15/439,343 US20170157038A1 (en) | 2008-11-13 | 2017-02-22 | Ophthalmic drug delivery method |
US16/398,174 US10842669B2 (en) | 2008-11-13 | 2019-04-29 | Ophthalmic drug delivery method |
US17/102,163 US20210069016A1 (en) | 2008-11-13 | 2020-11-23 | Neurodegenerative Disorder Treatment Method |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11414308P | 2008-11-13 | 2008-11-13 | |
US12/611,682 US20100119519A1 (en) | 2008-11-13 | 2009-11-03 | Ophthalmic drug delivery system and method |
US12/985,758 US20110125090A1 (en) | 2008-11-13 | 2011-01-06 | Ophthalmic drug delivery system and method |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/611,682 Continuation-In-Part US20100119519A1 (en) | 2008-11-13 | 2009-11-03 | Ophthalmic drug delivery system and method |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/457,568 Division US9486357B2 (en) | 2008-11-13 | 2012-04-27 | Ophthalmic drug delivery system and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110125090A1 true US20110125090A1 (en) | 2011-05-26 |
Family
ID=44062607
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/985,758 Abandoned US20110125090A1 (en) | 2008-11-13 | 2011-01-06 | Ophthalmic drug delivery system and method |
US13/457,568 Active 2031-10-21 US9486357B2 (en) | 2008-11-13 | 2012-04-27 | Ophthalmic drug delivery system and method |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/457,568 Active 2031-10-21 US9486357B2 (en) | 2008-11-13 | 2012-04-27 | Ophthalmic drug delivery system and method |
Country Status (1)
Country | Link |
---|---|
US (2) | US20110125090A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013096626A1 (en) * | 2011-12-20 | 2013-06-27 | Abbott Medical Optics Inc. | Implantable intraocular drug delivery apparatus, system and method |
US20140178475A1 (en) * | 2012-09-17 | 2014-06-26 | Bind Therapeutics, Inc. | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same |
US9877923B2 (en) | 2012-09-17 | 2018-01-30 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US9895378B2 (en) | 2014-03-14 | 2018-02-20 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same |
US10047072B2 (en) | 2013-09-16 | 2018-08-14 | Astrazeneca Ab | Therapeutic polymeric nanoparticles and methods of making and using same |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US10588855B2 (en) | 2008-05-12 | 2020-03-17 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11298262B2 (en) | 2018-07-23 | 2022-04-12 | The Regents Of The University Of Colorado, A Body Corporate | Ophthalmic device for drug delivery |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
US11399977B2 (en) | 2020-06-04 | 2022-08-02 | SpyGlass Pharma, Inc. | Ophthalmic implant system for drug delivery |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10842669B2 (en) | 2008-11-13 | 2020-11-24 | Gholam A. Peyman | Ophthalmic drug delivery method |
US10272035B2 (en) * | 2008-11-13 | 2019-04-30 | Gholam A. Peyman | Ophthalmic drug delivery method |
WO2014055999A2 (en) * | 2012-10-05 | 2014-04-10 | Kadmon Corporation, Llc | Treatment of ocular disorders |
EP3685855B1 (en) * | 2012-10-05 | 2023-11-22 | Kadmon Corporation, LLC | Human anti-vegfr-2/kdr antibodies |
US10881503B2 (en) | 2014-05-12 | 2021-01-05 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
US11666777B2 (en) | 2014-05-12 | 2023-06-06 | Gholam A. Peyman | Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient |
US11338059B2 (en) | 2014-05-12 | 2022-05-24 | Gholam A. Peyman | Method of corneal and scleral inlay crosslinking and preservation |
US11648261B2 (en) | 2014-05-12 | 2023-05-16 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
US11565023B2 (en) | 2014-05-12 | 2023-01-31 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
US10925889B2 (en) | 2014-05-12 | 2021-02-23 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
US11045352B2 (en) | 2014-05-12 | 2021-06-29 | Gholam A. Peyman | Methods for treatment of dry eye and other acute or chronic inflammatory processes |
US10583221B2 (en) | 2014-05-12 | 2020-03-10 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
FR3028410A1 (en) | 2014-11-18 | 2016-05-20 | Pierre Coulon | MULTIFUNCTIONAL CAPSULAR IMPLANT |
US11273072B2 (en) | 2017-01-13 | 2022-03-15 | Gyroscope Therapeutics Limited | Suprachoroidal injection device |
WO2019221959A1 (en) * | 2018-05-16 | 2019-11-21 | Peyman Gholam A | Method of treating, reducing, or alleviating a medical condition in a patient |
US11707518B2 (en) | 2019-04-28 | 2023-07-25 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4781675A (en) * | 1985-11-27 | 1988-11-01 | White Thomas C | Infusion cannula |
US5178604A (en) * | 1990-05-31 | 1993-01-12 | Iovision, Inc. | Glaucoma implant |
US5366501A (en) * | 1993-05-12 | 1994-11-22 | Langerman David W | Intraocular lens with dual 360 degree haptics |
US5370607A (en) * | 1992-10-28 | 1994-12-06 | Annuit Coeptis, Inc. | Glaucoma implant device and method for implanting same |
US5454796A (en) * | 1991-04-09 | 1995-10-03 | Hood Laboratories | Device and method for controlling intraocular fluid pressure |
US5628795A (en) * | 1995-03-15 | 1997-05-13 | Langerman David W | Spare parts for use in ophthalmic surgical procedures |
US5725493A (en) * | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US6096076A (en) * | 1992-08-07 | 2000-08-01 | Silvestrini; Thomas A. | Hybrid intrastromal corneal ring |
US6117675A (en) * | 1996-09-25 | 2000-09-12 | Hsc Research And Development Limited Partnership | Retinal stem cells |
US20020071855A1 (en) * | 2000-07-28 | 2002-06-13 | Anika Therapeutics, Inc | Bioabsorbable composites of derivatized hyaluronic acid and other biodegradable, biocompatible polymers |
US20030149479A1 (en) * | 2002-01-18 | 2003-08-07 | Snyder Michael E. | Endocapsular tension ring sustained release device and method of making and using the same |
US20030175324A1 (en) * | 2001-03-15 | 2003-09-18 | Robinson Michael R. | Ocular therapeutic agent delivery devices and methods for making and using such devices |
US6649625B2 (en) * | 1998-08-17 | 2003-11-18 | Senju Pharmaceutical Co., Ltd. | Agent for prophylaxis and treatment of glaucoma |
US20040132725A1 (en) * | 1999-11-09 | 2004-07-08 | Alexander Levitzki | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
US20040137059A1 (en) * | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
US20050064010A1 (en) * | 2003-09-18 | 2005-03-24 | Cooper Eugene R. | Transscleral delivery |
US20060106455A1 (en) * | 2004-11-12 | 2006-05-18 | Icon Interventional Systems, Inc. | Ostial stent |
US20070031472A1 (en) * | 2004-04-30 | 2007-02-08 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US20070093892A1 (en) * | 2005-10-20 | 2007-04-26 | Alcon Manufacturing, Ltd. | Maintaining preoperative position of the posterior lens capsule after cataract surgery |
US7276050B2 (en) * | 2004-03-02 | 2007-10-02 | Alan Franklin | Trans-scleral drug delivery method and apparatus |
US7278990B2 (en) * | 2004-07-19 | 2007-10-09 | Gwon Arlene E | Controlled ocular lens regeneration |
US20090155338A1 (en) * | 2005-09-21 | 2009-06-18 | Aston University | Chronotherapeutic Ocular Delivery System Comprising a Combination of Prostaglandin and a Beta-Blocker for Treating Primary Glaucoma |
US20100119519A1 (en) * | 2008-11-13 | 2010-05-13 | Peyman Gholam A | Ophthalmic drug delivery system and method |
US7794437B2 (en) * | 2003-01-24 | 2010-09-14 | Doheny Retina Institute | Reservoirs with subretinal cannula for subretinal drug delivery |
US7824704B2 (en) * | 2003-05-02 | 2010-11-02 | Surmodics, Inc. | Controlled release bioactive agent delivery device |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3096076A (en) * | 1959-07-03 | 1963-07-02 | Walli Ernst | Apparatus for gradually lifting construction parts manufactured on a building yard |
US5578042A (en) * | 1994-03-14 | 1996-11-26 | Cumming; J. Stuart | Ophthalmic kit and method for lens insertion |
DE4424753B4 (en) * | 1994-07-13 | 2004-07-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Retinal implant |
US6324429B1 (en) * | 1998-05-08 | 2001-11-27 | Massachusetts Eye And Ear Infirmary | Chronically implantable retinal prosthesis |
US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
FR2808993B1 (en) * | 2000-05-19 | 2002-09-06 | Corneal Ind | INJECTOR FOR FLEXIBLE IMPLANT |
EP1611877A1 (en) * | 2004-06-28 | 2006-01-04 | Universidade de Coimbra | Method for preparing sustained-release therapeutic ophthalmic articles using compressed fluids for impregnation of drugs |
US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
CN104623692A (en) * | 2006-03-08 | 2015-05-20 | 阿切埃米克斯股份有限公司 | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
US20080027304A1 (en) * | 2006-04-18 | 2008-01-31 | Pardo Geoffrey B | Intraocular pressure attenuation device |
US20080097335A1 (en) * | 2006-08-04 | 2008-04-24 | Allergan, Inc. | Ocular implant delivery assemblies |
US20090325959A1 (en) * | 2008-06-26 | 2009-12-31 | Vittitow Jason L | Method for treating ophthalmic diseases using rho kinase inhibitor compounds |
-
2011
- 2011-01-06 US US12/985,758 patent/US20110125090A1/en not_active Abandoned
-
2012
- 2012-04-27 US US13/457,568 patent/US9486357B2/en active Active
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4781675A (en) * | 1985-11-27 | 1988-11-01 | White Thomas C | Infusion cannula |
US5178604A (en) * | 1990-05-31 | 1993-01-12 | Iovision, Inc. | Glaucoma implant |
US5454796A (en) * | 1991-04-09 | 1995-10-03 | Hood Laboratories | Device and method for controlling intraocular fluid pressure |
US6096076A (en) * | 1992-08-07 | 2000-08-01 | Silvestrini; Thomas A. | Hybrid intrastromal corneal ring |
US5370607A (en) * | 1992-10-28 | 1994-12-06 | Annuit Coeptis, Inc. | Glaucoma implant device and method for implanting same |
US5366501A (en) * | 1993-05-12 | 1994-11-22 | Langerman David W | Intraocular lens with dual 360 degree haptics |
US5725493A (en) * | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US5830173A (en) * | 1994-12-12 | 1998-11-03 | Avery; Robert Logan | Intravitreal medicine delivery |
US5628795A (en) * | 1995-03-15 | 1997-05-13 | Langerman David W | Spare parts for use in ophthalmic surgical procedures |
US6117675A (en) * | 1996-09-25 | 2000-09-12 | Hsc Research And Development Limited Partnership | Retinal stem cells |
US6649625B2 (en) * | 1998-08-17 | 2003-11-18 | Senju Pharmaceutical Co., Ltd. | Agent for prophylaxis and treatment of glaucoma |
US20040132725A1 (en) * | 1999-11-09 | 2004-07-08 | Alexander Levitzki | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
US20020071855A1 (en) * | 2000-07-28 | 2002-06-13 | Anika Therapeutics, Inc | Bioabsorbable composites of derivatized hyaluronic acid and other biodegradable, biocompatible polymers |
US20030175324A1 (en) * | 2001-03-15 | 2003-09-18 | Robinson Michael R. | Ocular therapeutic agent delivery devices and methods for making and using such devices |
US7090888B2 (en) * | 2002-01-18 | 2006-08-15 | Snyder Michael E | Sustained release ophthalmological device and method of making and using the same |
US20030149479A1 (en) * | 2002-01-18 | 2003-08-07 | Snyder Michael E. | Endocapsular tension ring sustained release device and method of making and using the same |
US20040137059A1 (en) * | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
US7794437B2 (en) * | 2003-01-24 | 2010-09-14 | Doheny Retina Institute | Reservoirs with subretinal cannula for subretinal drug delivery |
US7824704B2 (en) * | 2003-05-02 | 2010-11-02 | Surmodics, Inc. | Controlled release bioactive agent delivery device |
US20050064010A1 (en) * | 2003-09-18 | 2005-03-24 | Cooper Eugene R. | Transscleral delivery |
US7276050B2 (en) * | 2004-03-02 | 2007-10-02 | Alan Franklin | Trans-scleral drug delivery method and apparatus |
US20070031472A1 (en) * | 2004-04-30 | 2007-02-08 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US7278990B2 (en) * | 2004-07-19 | 2007-10-09 | Gwon Arlene E | Controlled ocular lens regeneration |
US20060106455A1 (en) * | 2004-11-12 | 2006-05-18 | Icon Interventional Systems, Inc. | Ostial stent |
US20090155338A1 (en) * | 2005-09-21 | 2009-06-18 | Aston University | Chronotherapeutic Ocular Delivery System Comprising a Combination of Prostaglandin and a Beta-Blocker for Treating Primary Glaucoma |
US20070093892A1 (en) * | 2005-10-20 | 2007-04-26 | Alcon Manufacturing, Ltd. | Maintaining preoperative position of the posterior lens capsule after cataract surgery |
US20100119519A1 (en) * | 2008-11-13 | 2010-05-13 | Peyman Gholam A | Ophthalmic drug delivery system and method |
Non-Patent Citations (1)
Title |
---|
Yasuaki Hata, et al, Antiangiogenic Properties of Fasudil, a Potent Rho-kinase Inhibitor, 52 JPN. J OPHTHALMOL. 16 (February 2008 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US10588855B2 (en) | 2008-05-12 | 2020-03-17 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US11426306B2 (en) | 2009-05-18 | 2022-08-30 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US10111776B2 (en) | 2011-12-20 | 2018-10-30 | Johnson & Johnson Surgical Vision, Inc. | Implantable intraocular drug delivery apparatus, system and method |
WO2013096626A1 (en) * | 2011-12-20 | 2013-06-27 | Abbott Medical Optics Inc. | Implantable intraocular drug delivery apparatus, system and method |
US9241829B2 (en) | 2011-12-20 | 2016-01-26 | Abbott Medical Optics Inc. | Implantable intraocular drug delivery apparatus, system and method |
US20140178475A1 (en) * | 2012-09-17 | 2014-06-26 | Bind Therapeutics, Inc. | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same |
US9877923B2 (en) | 2012-09-17 | 2018-01-30 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
US20140248358A1 (en) * | 2012-09-17 | 2014-09-04 | Bind Therapeutics, Inc. | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same |
US20140249158A1 (en) * | 2012-09-17 | 2014-09-04 | Bind Therapeutics, Inc. | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same |
US11253394B2 (en) | 2013-03-15 | 2022-02-22 | Dose Medical Corporation | Controlled drug delivery ocular implants and methods of using same |
US10047072B2 (en) | 2013-09-16 | 2018-08-14 | Astrazeneca Ab | Therapeutic polymeric nanoparticles and methods of making and using same |
US10577351B2 (en) | 2013-09-16 | 2020-03-03 | Astrazeneca Ab | Therapeutic polymeric nanoparticles and methods of making and using same |
US9895378B2 (en) | 2014-03-14 | 2018-02-20 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same |
US10071100B2 (en) | 2014-03-14 | 2018-09-11 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
US11298262B2 (en) | 2018-07-23 | 2022-04-12 | The Regents Of The University Of Colorado, A Body Corporate | Ophthalmic device for drug delivery |
US11399977B2 (en) | 2020-06-04 | 2022-08-02 | SpyGlass Pharma, Inc. | Ophthalmic implant system for drug delivery |
US11617681B2 (en) | 2020-06-04 | 2023-04-04 | SpyGlass Pharma, Inc. | Ophthalmic implant system for drug delivery |
US11903874B2 (en) | 2020-06-04 | 2024-02-20 | SpyGlass Pharma, Inc. | Ophthalmic implant system for drug delivery |
Also Published As
Publication number | Publication date |
---|---|
US20120213841A1 (en) | 2012-08-23 |
US9486357B2 (en) | 2016-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9486357B2 (en) | Ophthalmic drug delivery system and method | |
US20100119519A1 (en) | Ophthalmic drug delivery system and method | |
JP5485314B2 (en) | Steroid intraocular implant that provides long-term sustained release for more than 2 months | |
US10842669B2 (en) | Ophthalmic drug delivery method | |
US20050181018A1 (en) | Ocular drug delivery | |
JP7026507B2 (en) | Methods and Biocompatible Compositions to Achieve Sustained Release of Drugs in the Eye | |
AU2018253472B2 (en) | Trans-sclera portal for delivery of therapeutic agents | |
PL196539B1 (en) | Ophthalmic drug delivery device | |
Sun et al. | Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-ε-caprolactone (PCL) | |
US20170157038A1 (en) | Ophthalmic drug delivery method | |
KR20020059630A (en) | Drug delivery device | |
JP2007505932A (en) | Transscleral delivery | |
CA2830555A1 (en) | Intraocular drug delivery device and associated methods | |
Nagaraj et al. | A review on recent advancements in ophthalmology devices: currently in market and under clinical trials | |
CN110337296A (en) | Intraocular drug delivery device and correlation technique | |
US10272035B2 (en) | Ophthalmic drug delivery method | |
Tekko et al. | Microneedles for ocular drug delivery and targeting: challenges and opportunities | |
US20210069016A1 (en) | Neurodegenerative Disorder Treatment Method | |
Suresh et al. | Ocular implants as drug delivery device in opthalmic therapeutics: An overview | |
Mackert | Cataract and Glaucoma | |
JP2015074641A (en) | Intraocular drug delivery device and accompanying method | |
RU2557925C1 (en) | Biodegradable multilayer implant for administering drug substances into vitreal cavity of eye | |
AU2019204106A1 (en) | Intraocular drug delivery device and associated methods | |
Wnek et al. | Ocular Implants for Drug Delivery/Susan S. Lee, Peng Yuan, Michael R. Robinson |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |